Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matrix Pharmaceutical offers 3.6 million shares:

This article was originally published in Clinica

Executive Summary

Matrix Pharmaceutical is offering 3.6 million shares at $13.25 each. Proceeds of $47.7 million are to be used for R&D, clinical testing and regulatory activities for Matrix' site-specific treatments for cancer and serious skin diseases. The company's most advanced products include the AccuSite gels and IntraDose injectable gel for delivering cancer therapeutics.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093724

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel